- Home
- NEOG vs CDTX Comparison
NEOG vs CDTX Comparison
Compare NEOG & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOG
- CDTX
- Stock Information
- Founded
- NEOG 1981
- CDTX 2012
- Country
- NEOG United States
- CDTX United States
- Employees
- NEOG N/A
- CDTX N/A
- Industry
- NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEOG Health Care
- CDTX Health Care
- Exchange
- NEOG Nasdaq
- CDTX Nasdaq
- Market Cap
- NEOG 1.1B
- CDTX 980.1M
- IPO Year
- NEOG 1989
- CDTX 2015
- Fundamental
- Price
- NEOG $4.74
- CDTX $61.05
- Analyst Decision
- NEOG Buy
- CDTX Strong Buy
- Analyst Count
- NEOG 2
- CDTX 11
- Target Price
- NEOG $7.50
- CDTX $52.11
- AVG Volume (30 Days)
- NEOG 6.4M
- CDTX 1.6M
- Earning Date
- NEOG 07-29-2025
- CDTX 08-12-2025
- Dividend Yield
- NEOG N/A
- CDTX N/A
- EPS Growth
- NEOG N/A
- CDTX N/A
- EPS
- NEOG N/A
- CDTX N/A
- Revenue
- NEOG $905,996,000.00
- CDTX $302,000.00
- Revenue This Year
- NEOG N/A
- CDTX N/A
- Revenue Next Year
- NEOG N/A
- CDTX N/A
- P/E Ratio
- NEOG N/A
- CDTX N/A
- Revenue Growth
- NEOG N/A
- CDTX N/A
- 52 Week Low
- NEOG $3.87
- CDTX $10.14
- 52 Week High
- NEOG $18.58
- CDTX $61.19
- Technical
- Relative Strength Index (RSI)
- NEOG 41.48
- CDTX 75.12
- Support Level
- NEOG $4.94
- CDTX $50.25
- Resistance Level
- NEOG $5.38
- CDTX $55.75
- Average True Range (ATR)
- NEOG 0.29
- CDTX 3.96
- MACD
- NEOG -0.00
- CDTX -0.04
- Stochastic Oscillator
- NEOG 21.17
- CDTX 95.28
About NEOG Neogen Corporation
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.